Immune Checkpoint Inhibitors in the Treatment of HCC.

Front Oncol · 2020 · PMC7874239 · PMID 33585218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Although the design of the studies was different, phase III data were interesting thanks to the best tolerability of the drug in the patients, along with a positive trend in terms of response rate and overall survival.

also in 10,439 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.